Ovid Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
KCC2 direct activation is a transformative approach for psychotic disorders, with OV4071 showing strong preclinical efficacy and safety. The clinical strategy uses translational biomarkers for rapid proof-of-concept in schizophrenia, Parkinson’s disease psychosis, and Lewy body dementia, backed by broad IP and significant commercial potential.
-
The company is advancing OV329, a novel GABA-AT inhibitor, into Phase II for epilepsy with promising safety and efficacy data, while also progressing OV4071, a KCC2 activator, into Phase I for CNS disorders including psychosis. Interim and pivotal data readouts are expected over the next year.
-
The company is advancing a CNS-focused pipeline with differentiated mechanisms, highlighted by OV329 for epilepsy, which shows strong efficacy and tolerability, and OV4071, a KCC2 activator targeting psychosis. Key clinical milestones are expected over the next 6–18 months.
Fiscal Year 2025
-
Regulatory clearance for OV4071 and strong safety data for OV329 drive pipeline expansion, supported by $60M PIPE financing and potential $53M from warrant exercises, extending cash runway into 2029. New clinical programs target significant unmet needs in epilepsy and psychosis.
-
Phase I results for OV329 in healthy volunteers showed a strong safety profile, no ocular toxicity, and robust GABAergic inhibition exceeding that of vigabatrin. The data support advancing to a phase II-A trial in treatment-resistant focal onset epilepsy, with a 7 mg dose selected for optimal efficacy and safety.
-
OV329, a next-generation GABA-AT inhibitor, is advancing through a biomarker-rich phase I study with a readout expected in late Q3 2025. Early data show strong safety and target engagement, supporting plans for phase II-A in drug-resistant focal seizures and a differentiated market position.
-
The presentation detailed a differentiated CNS pipeline focused on precision small molecules, highlighting OV329’s progress toward phase II for treatment-resistant epilepsy and the first-in-class KCC2 activators targeting psychosis in Parkinson’s and Lewy body dementia. Key milestones include multiple clinical readouts in 2024–2025 and a strong cash position to support ongoing development.
-
The presentation detailed a differentiated neurotherapeutics pipeline, highlighting OV329’s promising safety and efficacy profile in epilepsy and the KCC2 platform’s first-in-human milestone for psychosis. Multiple clinical readouts and strong capital position support strategic growth.
-
The conference highlighted a robust pipeline targeting neuronal hyperexcitability, with OV-329 advancing toward key safety and biomarker data in 2024 and a diverse KCC2 platform entering first-in-human trials. The paused ROCK2 program may resume pending external trial outcomes.
Fiscal Year 2024
-
A robust pipeline of direct KCC2 activators is advancing toward first-in-human studies, targeting neuronal hyper-excitability in CNS disorders. OV350 leads with a phase I trial planned for early 2025, supported by strong preclinical efficacy and safety data. Strategic focus includes broad indication potential, disciplined resource use, and partnering flexibility.